Dana-Farber Cancer Institute (Main)
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Accepting patients
SL-172154
An Open-Label Phase 1a/1b Dose Escalation and Expansion Cohort Study of SL-172154 (SIRPα-Fc-CD40L) in Combination With Azacitidine or With Azacitidine and Venetoclax for the Treatment of Subjects With Higher-Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Learn more- Phase 1
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
MORE
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Learn more- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- Maintenance
- Phase 2
Accepting patients
BXCL701
A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2
Learn more- Dipeptidyl Peptidase 4 (DPP-4) Inhibitor
- Phase 1
Accepting patients
SL-401
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
AZD6738
A Phase Ib Study of AZD6738 for Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Front-Line Therapy
Learn more- Kinase Inhibitor
- Phase 1
Accepting patients
ARC-T Cells Plus SPRX002
Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
Learn more- CAR T Cell
- Phase 1
Accepting patients
IS-free Treg Stem Cell Transplant
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory AML/MDS
Learn more- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Venetoclax in Pre- and Post-Transplant Therapy
A Phase 1 Study of Adding Venetoclax to a Reduced Intensity Conditioning Regimen and to Maintenance in Combination With a Hypomethylating Agent After Allogeneic Hematopoietic Cell Transplantation for Patients With High Risk AML, MDS, and MDS/MPN Overlap Syndromes
Learn more- Allogeneic Stem Cell Transplant
- Antimetabolites
- BCL-2 Inhibitor
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1
Accepting patients
Ipilimumab Plus Donor Lymphocyte Infusion
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
Learn more- Donor Lymphocyte Infusion (DLI)
- Monoclonal Antibody
- CD25
- CTLA-4
- Phase 1
Filters
Save & Share
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Advanced Filters
Hide Trials
These are additional options that allow you to hide (or filter out) trial options that may not be right for you.
Trial Enrollment Status
Treatment Classifications
Filter results based on treatment classifications/type.
Trial Type
Phase
MDS Classification
Has your MDS been classified as primary (cause unknown) or secondary (treatment related)?